{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:48:37Z","timestamp":1772930917666,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,2,19]],"date-time":"2008-02-19T00:00:00Z","timestamp":1203379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1038\/ncponc1071","type":"journal-article","created":{"date-parts":[[2008,2,19]],"date-time":"2008-02-19T14:11:51Z","timestamp":1203430311000},"page":"234-238","source":"Crossref","is-referenced-by-count":9,"title":["Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis"],"prefix":"10.1038","volume":"5","author":[{"given":"Huy","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ujjwal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Nourse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher K","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,19]]},"reference":[{"key":"BFncponc1071_CR1","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M  et al. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104: 634\u2013641","journal-title":"Blood"},{"key":"BFncponc1071_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD  et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579\u2013586","journal-title":"J Clin Oncol"},{"key":"BFncponc1071_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/hon.767","volume":"24","author":"F Bertoni","year":"2006","unstructured":"Bertoni F  et al. (2006) Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 24: 22\u201327","journal-title":"Hematol Oncol"},{"key":"BFncponc1071_CR4","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","volume":"101","author":"J Orchard","year":"2003","unstructured":"Orchard J  et al. (2003) A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101: 4975\u20134981","journal-title":"Blood"},{"key":"BFncponc1071_CR5","first-page":"270","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"NL Harris","year":"2001","unstructured":"Harris NL and Swerdlow SH (2001) Methotrexate-associated lymphoproliferative disorders. In Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 270\u2013271 (Eds Jaffe ES  et al.). Lyon: International Agency for Research on Cancer Press"},{"key":"BFncponc1071_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1586\/14787210.4.1.77","volume":"4","author":"MK Gandhi","year":"2006","unstructured":"Gandhi MK (2006) Epstein-Barr virus-associated lymphomas. Expert Rev Anti Infect Ther 4: 77\u201389","journal-title":"Expert Rev Anti Infect Ther"},{"key":"BFncponc1071_CR7","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","volume":"99","author":"X Mariette","year":"2002","unstructured":"Mariette X  et al. (2002) Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99: 3909\u20133915","journal-title":"Blood"},{"key":"BFncponc1071_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","volume":"328","author":"OW Kamel","year":"1993","unstructured":"Kamel OW  et al. (1993) Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328: 1317\u20131321","journal-title":"N Engl J Med"},{"key":"BFncponc1071_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncponc0107","volume":"2","author":"R Khanna","year":"2005","unstructured":"Khanna R  et al. (2005) Technology Insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat Clin Pract Oncol 2: 138\u2013149","journal-title":"Nat Clin Pract Oncol"},{"key":"BFncponc1071_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/jnci\/djh313","volume":"96","author":"WH Feng","year":"2004","unstructured":"Feng WH  et al. (2004) Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 96: 1691\u20131702","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc1071_CR11","volume-title":"Haematology: Basic Principles and Practice","author":"R Hoffman","year":"2005","unstructured":"Hoffman R  et al. (2005) Haematology: Basic Principles and Practice, edn 4. Philadelphia: Elsevier Churchill Livingstone"},{"key":"BFncponc1071_CR12","first-page":"242","volume":"84","author":"ML Ghirardelli","year":"1999","unstructured":"Ghirardelli ML  et al. (1999) Diagnostic approach to lymph node enlargement. Haematologica 84: 242\u2013247","journal-title":"Haematologica"},{"key":"BFncponc1071_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-2008-1041067","volume":"14","author":"DB Sanders","year":"1994","unstructured":"Sanders DB (1994) Lambert-Eaton myasthenic syndrome: pathogenesis and treatment. Semin Neurol 14: 111\u2013117","journal-title":"Semin Neurol"},{"issue":"Suppl 4","key":"BFncponc1071_CR14","doi-asserted-by":"publisher","first-page":"iv12","DOI":"10.1093\/annonc\/mdj992","volume":"17","author":"AD Zelenetz","year":"2006","unstructured":"Zelenetz AD (2006) Mantle cell lymphoma: an update on management. Ann Oncol 17 (Suppl 4): iv12\u201314","journal-title":"Ann Oncol"},{"key":"BFncponc1071_CR15","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G  et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984\u20131992","journal-title":"J Clin Oncol"},{"key":"BFncponc1071_CR16","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R  et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104: 3064\u20133071","journal-title":"Blood"},{"key":"BFncponc1071_CR17","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M  et al. (2005) Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16: 1675\u20131682","journal-title":"Ann Oncol"},{"key":"BFncponc1071_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00277-005-1050-4","volume":"84","author":"K Takagi","year":"2005","unstructured":"Takagi K  et al. (2005) Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol 84: 548\u2013550","journal-title":"Ann Hematol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc1071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1071","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:51:34Z","timestamp":1684443094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc1071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,19]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["BFncponc1071"],"URL":"https:\/\/doi.org\/10.1038\/ncponc1071","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,19]]}}}